Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?

Gut

Volumn 52, Issue 4, 2003, Pages 486-489

  Dar, M S ^a   Goldblum, J R ^a   Rice, T W ^a   Falk, G W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER CLASSIFICATION; CANCER RISK; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DYSPLASIA; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; BIOPSY; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROSPECTIVE STUDIES; RISK FACTORS; SINGLE-BLIND METHOD;

EID: 0345700278     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.4.486     Document Type: Article

References (28)

1. Lee RG. Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients. Am J Surg Pathol 1985;9:845-52.
2. Altorki NK, Sunagawa M, Little AG, et al. High-grade dysplosia in the columnar- lined esophagus. Am J Surg 1991;161:97-100.
3. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's esophagus. Gut 1991;32:1441-6.
4. Pera NI, Trastek VF, Carpenter HA, et al. Barrett's esophagus with high-grade dysplasia: on indication for esophogectomy? Ann Thorac Surg 1992;54:199-204.
5. Rice TW, Falk GW, Achkar E, et al. Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 1993;88:1832-36.
6. Edwards MJ, Gable DR, Lentsch AB, et al. The rationale for esophogectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Ann Surg 1996;223:585-91.
7. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia: an indication for prophylactic esophagectomy. Ann Surgery 1996;224:66-71.
8. Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathologic study. Am J Gastroenterol 1997;92:586-91.
9. Ferguson MK, Naunheim KS. Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg 1997;114:824-49.
10. Folk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointestinal Endosc 1999;49:170-6.
11. Zaninotto G, Parenti AR, Ruol A, et al. Oesophageal resection for high-grade dysplasia in Barrett's oesophagus. Br J Surg 200;87:1102-5.
12. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high. grade dysplasia. Am J Gastroenterol 2000;95:1888-93.
13. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
14. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
15. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low. and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
16. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105:40-50.
17. Overholt BF, Paniehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999;49:1-7.
18. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998;114:448-55.
19. Rice TW, Blackstone EH, Goldblum JR, et al. Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg 2001;122:1077-90.
20. Holscher AH, Bollschweiler, Schneider PM, et al. Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma. Cancer 1995;76:178-86.
21. Sabik JF, Rice TW, Goldblum JR, et al. Superficial esophageal carcinoma. Ann Thorac Surg 1995;60:896-902.
22. Pellegrini CA, Pohl D. High-grade dysplosia in Barrett's esophagus: surveillance or operation? J Gastrointest Surg 2000;4:131-4.
23. Reid BJ, Blount PL, Feng Z, et al. Optimizing endoscopic biopsy detection of early cancer in Borrett's high-grade dysplosio. Am J Gastroenterol 2000;95:3089-96.
24. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplosia in Barrett's esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
25. Ormsby AH, Petros RE, Hendricks WH, et al. Interobserver variation in Borrett's related high grade dysplosio and superficial carcinoma: can it be improved using uniform pathological criteria? Gut 2002;51:671-6.
26. Reid BJ, Prevo U, Golipeou PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosily identifies o patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
27. Kirby JD. Quality of life after esophogectomy: the patients' perspective. Dis Esophagus 1999;12:168-71.
28. Haggitt RC. Borrett's esophagus, dysplosia, and adenocarcinoma. Hum Pathol 1994;25:982-93.